Maintenance of natalizumab during the first trimester of pregnancy in active multiple sclerosis

SPECIAL REPORT

Multiple Sclerosis

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis

The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study

Pediatr Neurol.

Alroughani R, Ahmed SF, Behbehani R, Al-Hashel J

doi: 10.1016/

Multiple Sclerosis

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

J Neurol.

Kamm CP, Barin L, Gobbi C, Pot C, Calabrese P, Salmen A, Achtnichts L, Kesselring J, Puhan MA, von Wyl V, Swiss Multiple Sclerosis Registry (SMSR).

doi: 10.1007/s00415-019-09563-y.

ECTRIMS 2019

Multiple Sclerosis

Multiple Sclerosis During Pregnancy

Multiple Sclerosis

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis

Eur J Neurol.

Boremalm M, Juto A, Axelsson M, Novakova L, Frisell T, Svenningsson A, Lycke J, Piehl F, Salzer J

doi: 10.1111/ene.13936.

Multiple Sclerosis

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Cochrane Database Syst Rev.

Filippini G, Del Giovane C, Clerico M, Beiki O, Mattoscio M, Piazza F, Fredrikson S, Tramacere I, Scalfari A, Salanti G

doi: 10.1002/

Multiple Sclerosis

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Ther Adv Neurol Disord.

Prosperini L, Kinkel RP, Miravalle AA, Iaffaldano P, Fantaccini S

doi: 10.1177/

SPECIAL REPORT

Multiple Sclerosis

Vaccination Readiness in Multiple Sclerosis

Multiple Sclerosis

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension

Lancet Neurol.

Kapoor R, Ho PR, Campbell N, Chang I, Deykin A, Forrestal F, Lucas N, Yu B, Arnold DL, Freedman MS, Goldman MD, Hartung HP, Havrdová EK, Jeffery D, Miller A, Sellebjerg F, Cadavid D, Mikol D, Steiner D

doi: 10.1016/S1474-4422

Related content

Long-Term Real-World Use of Natalizumab Over 10 Years in Relapsing-Remitting Multiple Sclerosis

The Use of Natalizumab in Pediatric Patients With Active Relapsing Multiple Sclerosis: A Prospective Study

Factors influencing patient satisfaction with the first diagnostic consultation in multiple sclerosis: a Swiss Multiple Sclerosis Registry (SMSR) study.

Multiple Sclerosis During Pregnancy

Natalizumab, rituximab and fingolimod as escalation therapy in multiple sclerosis

Treatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis

Post-natalizumab disease reactivation in multiple sclerosis: systematic review and meta-analysis

Vaccination Readiness in Multiple Sclerosis

Effect of natalizumab on disease progression in secondary progressive multiple sclerosis (ASCEND): a phase 3, randomised, double-blind, placebo-controlled trial with an open-label extension